PRKCB and B-cell chronic lymphocytic leukemia: Our experiments using mithramycin are robust because we observed that this agent effectively displaced SP1 from its binding sites within the proximal promoter of PRKCB both in MEC1 and in primary CLL cells, an observation consistent with reported effects of this drug on this22 and other genes29, 30.